# Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.

> **NCT02909036** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 46 (actual)

## Conditions studied

- Multiple Myeloma
- Amyloidosis

## Interventions

- **DEVICE:** Melphalan
- **DRUG:** Pegfilgrastim
- **PROCEDURE:** Autologous Hematopoietic Progenitor Cell Transplant

## Key facts

- **NCT ID:** NCT02909036
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-09
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02909036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02909036, "Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02909036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*